Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

HRV Pharma’s innovative “virtual manufacturing” model connects FDA-approved facilities to prevent prescription shortages and ...

Smaller pharmaceutical companies in Europe are now bracing to be the focus of the Trump administration’s lobbying after 16 of ...

A facility that manufactures products for pharmaceutical companies is set to eliminate one of its two Massachusetts ...

Trump unveiled a new healthcare plan that calls for lower drug prices, reduced insurance premiums and price transparency.

ACA Pharma: [email protected] Azurity Pharmaceuticals: [email protected] ...

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical ...

Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools ...

While 2025 was the year of disruption for Trump’s pharma policies, we expect 2026 to be the year of truth: will the US ...

Rounding up five deals in the pharma commercialization segment, and delving into trends driving that activity; a discussion ...

Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s ...